Agennix AG / Agennix Announces Upcoming Data Presentation from Talactoferrin Phase 2 Trial in Severe Sepsis at American Thoracic Society International Conference on May 17  processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. 

Martinsried/Munich  (Germany),  Princeton,  NJ  and  Houston, TX, May 12, 2010 -
Agennix  AG (Frankfurt Stock  Exchange: AGX) today  announced that data from the
talactoferrin  Phase 2 trial in severe sepsis  will be presented at the upcoming
International  Conference of the American Thoracic Society (ATS) in New Orleans,
LA.  The presentation, which is  entitled, "Talactoferrin Alfa Reduces Mortality
in   Severe   Sepsis:   Results  of  a  Phase  2 Randomized,  Placebo-Controlled
Double-Blind  Study," will be part of a mini-symposium, New Treatment Approaches
for  Lung Disease: Late Breaking Abstracts.  The data will be presented at 9:45
AM  CDT on  Monday, May  17, 2010 by K.  Guntupalli, M.D.,  Professor and Chief,
Pulmonary  Critical  Care  and  Sleep  Medicine,  Baylor College of Medicine and
principal investigator of the talactoferrin trial.
About Agennix
Agennix  AG is  a publicly  traded biopharmaceutical  company that is developing
novel  therapies in areas of major unmet  medical need to improve the length and
quality  of life of seriously ill  patients. The Company's most advanced program
is  talactoferrin, an oral therapy that has demonstrated activity in randomized,
double-blind,  placebo-controlled Phase 2 studies in non-small cell lung cancer,
as  well as  in severe  sepsis. Talactoferrin  is currently  in Phase 3 clinical
trials  in non-small cell lung cancer, and Agennix plans to develop this program
further  for the treatment of severe sepsis. Other clinical development programs
include  RGB-286638, a multi-targeted  kinase inhibitor in  Phase 1 testing; the
oral   platinum-based   compound   satraplatin;   and  a  topical  gel  form  of
talactoferrin  for  diabetic  foot  ulcers.  Agennix's  registered  seat  is  in
Heidelberg,    Germany.    The   Company   has   three   sites   of   operation:
Martinsried/Munich,  Germany;  Princeton,  New  Jersey  and  Houston, Texas. For
additional information, please visit the Agennix Web site at www.agennix.com.
This  press  release  contains  forward-looking  statements,  which  express the
current  beliefs  and  expectations  of  the  management  of  Agennix  AG.  Such
statements  are  based  on  current  expectations  and  are subject to risks and
uncertainties,  many of  which are  beyond our  control, that could cause future
results,  performance or achievements to  differ significantly from the results,
performance  or  achievements  expressed  or  implied  by  such  forward-looking
statements.  There can be no guarantee  that talactoferrin will be developed for
severe  sepsis  in  a  timely  manner,  if  at  all,  or that talactoferrin will
ultimately  be approved  for sale  in any  country. Actual  results could differ
materially  depending on a  number of factors,  and we caution  investors not to
place  undue reliance on the forward-looking  statements contained in this press
release.  Forward-looking statements speak only as of the date on which they are
made  and  Agennix  undertakes  no  obligation  to  update these forward-looking
statements, even if new information becomes available in the future.


For further information, please contact:
Agennix AG
Investor Relations & Corporate Communications
Phone: +49 (0)89 8565 2693
ir@agennix.com 

In the U.S.:
Laurie Doyle
Director, Investor Relations & Corporate Communications
Phone: +1 609 524 5884
laurie.doyle@agennix.com 

Additional media contacts for Europe:
MC Services AG
Phone: +49 89 210 2280


Raimund Gabriel
raimund.gabriel@mc-services.eu 


Hilda Juhasz
hilda.juhasz@mc-services.eu 


Additional investor contact for Europe:
Trout International LLC

Lauren Williams, Vice President

Phone: +44 207 936 9325
lwilliams@troutgroup.com 



[HUG#1415153]



 --- End of Message --- 

Agennix AG
Im Neuenheimer Feld 515 Heidelberg Germany

ISIN: DE000A1A6XX4;
Listed: Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;